Search results :

	Unregistered User Click here if this is not your Personal Edition
		Contact Us \| Free E-Mail Updates \| Journals \| Register a colleague

EXPLORE : Most Read News All News All Webcasts / CME All Cases Congress Resource Centre All Medical Resources My Personal Edition


	12/16/2003	Non-Treatment-Related Chronic Myeloid Leukaemia As A Secondary Haematological Malignancy Appears Linked To Older Age
	05/07/2001	Increased Carboxymethyllysine In Dermis Of Patients With Chronic Renal Failure
	11/22/2006	Sprycel(TM) (Dasatinib) Approved in Europe -- The First Significant Advance for Treatment-Resistant Cml and Ph+ All Leukaemia Patients in 5 Years
	08/13/2002	NICE recommends funding for Glivec in England and Wales for treatment of patients with chronic myeloid leukemia
	12/06/2004	Continuous Imatinib Therapy for 4 Years Improves Chronic Myeloid Leukemia Survival: Presented at ASH
	02/23/2004	Vascular Endothelial Growth Factor Appears to Decrease In Chronic Myeloid Leukemia Patients Treated With Imatinib
	06/03/2002	Oxidative Marker Found In Rheumatoid Arthritis Synovial Tissue
	03/25/2008	Experimental Drug May Help Patients With Drug-Resistant Chronic Myeloid Leukaemia
	12/10/2007	New Data Show Glivec� Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
	11/28/2007	Tasigna� Gains European Approval for Patients With a Life-Threatening Form of Leukemia Who Are Resistant Or Intolerant to Existing Therapies
	10/30/2007	Tasigna� (Nilotinib) Receives U.S. Approval for Chronic Myeloid Leukemia in Patients With Resistance or Intolerance to Existing Therapies
	06/08/2007	Imatinib May Be Safer Than Dasatinib for Chronic Myeloid Leukaemia: Presented at EHA
	04/10/2006	Dasatinib Controls Chronic Myelogenous Leukemia in Gleevec-Resistant Patients: Presented at AACR
	12/29/2005	Bristol-Myers Squibb Submits New Drug Application for Dasatinib
	09/24/2001	Health Canada Approves Gleevec (Imatinib) For Chronic Myeloid Leukemia
	05/02/2005	Researchers Show New Drug May Help Treat Certain Forms of Leukemia
	11/29/2001	FDA Grants Orphan Drug Designation To Trisenox (Arsenic Trioxide) For Treatment Of Chronic And Acute Myeloid Leukemia
	11/17/1999	Leukemia-Fighting Drug Produces Dramatic Results In Clinical Trials
	05/03/2001	Trisenox (Arsenic Trioxide) Enhances Effects of Glivec (STI-571) Against Chronic Myeloid Leukemia
	12/05/2000	Experimental Medication Glivec (STI-571) Shows Promise Against Chronic Myelogenous Leukemia: Presented at ASH
	12/06/2004	New Treatment for Imatinib-Resistant Leukemia: Presented at ASH
	11/04/2004	Cytokine Genes Linked to Chronic Myeloid Leukemia: Presented at ESMO
	10/14/2004	Imatinib-based Therapy Results in Sustained Remission But Rarely Cures Chronic Myelogenous Leukemia: Presented at Leukemia 2004
	06/15/2004	BCR-ABL Positive Leukaemias Show Increasing Resistance to Imatinib Therapy: Presented at EHA
	12/09/2001	Glivec Data on Patients with Chronic Myelogenous Leukaemia Promising: Presented at ASH
	02/28/2002	Promising Results For Imatinib In Chronic Myelogenous Leukaemia
	06/02/2004	Imatinib Should Be First-Line Therapy for Patients With Chronic Myeloid Leukaemia
	06/09/2009	Suboptimal Response of Imatinib 400 mg in Chronic Myeloid Leukaemia Indicates Need for Early Intervention: Presented at EHA
	06/25/2008	Activation of LYN Kinase Is Associated With Imatinib Resistance in CML Patients
	06/17/2008	Frontline Dasatinib Demonstrates Rapid Response in Patients With Previously Untreated Chronic-Phase Chronic Myeloid Leukaemia: Presented at EHA
	11/09/2007	FDA Approves New Sprycel(R) (Dasatinib) Product Labeling for Patients With Chronic-Phase CML
	04/11/2006	Researchers Seek Alternative for Leukemia Patients Resistant to Standard Therapies
	12/15/2005	Dasatinib Therapy for Chronic Myeloid Leukemia Shows Promise: Presented at ASH
	12/12/2005	AMN107 May Benefit Leukemia Patients Resistant to Gleevec: Presented at ASH
	12/12/2005	Cell Genesys Reports Positive Results from Phase 2 Trial of GVAX Vaccine for Chronic Myelogenous Leukemia
	01/26/2004	Survival Outcome in Chronic-Phase Chronic Myelogenous Leukaemia Appears Better With Imatinib Mesylate Therapy Than For Past Non-Imatinib Treatments
	10/26/2004	FDA Grants Orphan Drug Designation to 17-AAG for Treatment of Chronic Myelogenous Leukemia
	04/13/2004	Higher Doses Of Imatinib Appear Effective, Safe Treatment for Chronic Myelogenous Leukemia
	04/01/2004	Higher Doses Of Imatinib Proven Effective And Safe in Treatment of Chronic Myelogenous Leukemia
	12/23/2002	FDA Approves Gleevec (Imatinib Mesylate) For Treatment Of Chronic Myeloid Leukemia
	06/16/2004	Downregulation of Putative Tumour Suppressor Gene Seen in Acute Myeloid Leukaemia, Chronic Myeloid Leukaemia and Myelodysplastic Syndromes: Presented at EHA
	06/23/2003	Karyotypic Response Associated with BCR-ABL Reduction in Imatinib Treatment of Chronic Myelogenous Leukaemia: Presented at EHA
	12/10/2001	Glivec (Imatinib Mesylate) May Be New standard of Care for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: Presented at ASH
	05/27/2004	Erythropoietin Effective in Treating Anaemia in Patients With Chronic Myeloid Leukaemia
	12/29/2003	Filgrastim-Induced Stem Cell Mobilisation During Imatinib Therapy Appears Safe, Feasible In Chronic Myeloid Leukaemia Patients
	10/24/2003	Imatinib is Effective Therapy for Chronic Myeloid Leukaemia in Patients Resistant or Intolerant to Interferon Therapy
	09/29/2003	Survival Benefit With Salvage Imatinib Mesylate For Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukaemia
	05/20/2003	Imatinib May Help Improve Prognosis Of Chronic Myeloid Leukaemia With Derivative Chromosome 9 Deletions
	10/13/2000	Donor Leukocyte Infusion Reduces Incidence Of Graft-versus-host disease
	12/07/2008	Low Toxicity Profile for Long-Term Imatinib Use in Chronic Myeloid Leukaemia: Presented at ASH